| 2026-08-10 | Press release | Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference |
| 2026-08-04 | Press release | Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference |
| 2026-08-04 | Press release | Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman |
| 2026-07-15 | Earnings deck | Presentation |
| 2026-07-15 | Press release | Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026 |
| 2026-07-15 | Press release | Johnson & Johnson reports Q2 2026 results, raises 2026 outlook |
| 2026-07-15 | Earnings deck | Download(opens in new window) |
| 2026-07-14 | Press release | 2Q26 Other Financial Disclosures (PDF) |
| 2026-07-14 | Press release | 2026 Second-Quarter Press Release & Supplemental Schedules |
| 2026-07-08 | Press release | Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform |
| 2026-06-26 | Press release | Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress |
| 2026-06-13 | Press release | New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength |
| 2026-06-11 | Press release | IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study |
| 2026-06-08 | Press release | Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Pl |
| 2026-06-03 | Press release | Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) di |
| 2026-05-27 | Press release | Press Release(opens in new window) |
| 2026-04-20 | Fact sheet | Investor fact sheet |
| 2026-01-21 | Press release | Press release(opens in new window) |
| 2025-07-15 | Press release | Press release(opens in new window) |
| 2025-04-16 | Press release | Press Release(opens in new window) |
| 2025-04-15 | Earnings deck | Presentation(opens in new window) |
| 2025-04-07 | Press release | Press Release(opens in new window) |
| 2024-04-16 | Earnings deck | Presentation(opens in new window) |
| 2024-04-16 | Press release | Press Release(opens in new window) |
| 2024-01-23 | Earnings deck | Earnings Presentation(opens in new window) |
| 2023-10-17 | Earnings deck | Earnings Presentation(opens in new window) |
| 2023-04-18 | Presentation | 2023 First-Quarter Infographic & Earnings Presentation |
| Press release | CHMP recommendation advances Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab as a potential standard o |